SIHUAN PHARM (00460): NMPA Accepts Marketing Application for Semaglutide Injection Developed by Huisheng Biopharmaceutical

Stock News

2025/08/15

SIHUAN PHARM (00460) announced that the marketing application for semaglutide injection developed by its non-wholly owned subsidiary Huisheng Biopharmaceutical Co., Ltd. has been accepted by the National Medical Products Administration (NMPA) for improving blood glucose control in adults with Type 2 diabetes. Additionally, the weight loss indication for semaglutide injection has completed Phase III clinical enrollment and is currently in the follow-up stage.

According to reports, semaglutide injection is a once-weekly long-acting GLP-1 receptor agonist (GLP-1RA) that activates GLP-1 receptors to enhance insulin secretion in a glucose-dependent manner, suppress glucagon secretion, and delay gastric emptying, thereby achieving blood glucose reduction effects. Meanwhile, semaglutide can reduce appetite and food intake, helping patients decrease caloric consumption and achieve weight reduction.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1113120887"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1113120887\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1113120887?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-15 19:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1113120887","market":"nz","top_or_hot":-1,"title":"SIHUAN PHARM (00460): NMPA Accepts Marketing Application for Semaglutide Injection Developed by Huisheng Biopharmaceutical","media":"Stock News","content":"<p>SIHUAN PHARM (00460) announced that the marketing application for semaglutide injection developed by its non-wholly owned subsidiary Huisheng Biopharmaceutical Co., Ltd. has been accepted by the National Medical Products Administration (NMPA) for improving blood glucose control in adults with Type 2 diabetes. Additionally, the weight loss indication for semaglutide injection has completed Phase III clinical enrollment and is currently in the follow-up stage.</p>\n<p>According to reports, semaglutide injection is a once-weekly long-acting GLP-1 receptor agonist (GLP-1RA) that activates GLP-1 receptors to enhance insulin secretion in a glucose-dependent manner, suppress glucagon secretion, and delay gastric emptying, thereby achieving blood glucose reduction effects. Meanwhile, semaglutide can reduce appetite and food intake, helping patients decrease caloric consumption and achieve weight reduction.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SIHUAN PHARM (00460): NMPA Accepts Marketing Application for Semaglutide Injection Developed by Huisheng Biopharmaceutical</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSIHUAN PHARM (00460): NMPA Accepts Marketing Application for Semaglutide Injection Developed by Huisheng Biopharmaceutical\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-08-15 19:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SIHUAN PHARM (00460) announced that the marketing application for semaglutide injection developed by its non-wholly owned subsidiary Huisheng Biopharmaceutical Co., Ltd. has been accepted by the National Medical Products Administration (NMPA) for improving blood glucose control in adults with Type 2 diabetes. Additionally, the weight loss indication for semaglutide injection has completed Phase III clinical enrollment and is currently in the follow-up stage.</p>\n<p>According to reports, semaglutide injection is a once-weekly long-acting GLP-1 receptor agonist (GLP-1RA) that activates GLP-1 receptors to enhance insulin secretion in a glucose-dependent manner, suppress glucagon secretion, and delay gastric emptying, thereby achieving blood glucose reduction effects. Meanwhile, semaglutide can reduce appetite and food intake, helping patients decrease caloric consumption and achieve weight reduction.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1600","symbol_name":"工业大麻","start_time":0,"source_url":"","article_id":"1113120887","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1113120887","pubTimestamp":1755258019,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"SIHUAN PHARM (00460) announced that the marketing application for semaglutide injection developed by its non-wholly owned subsidiary Huisheng Biopharmaceutical Co., Ltd. has been accepted by the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1600":"工业大麻","BK1515":"抗疫概念","BK1191":"制药","00460":"四环医药","BK1593":"医美概念股"},"translate_title":"四环医药(00460)：NMPA受理惠升生物制药研发的司美格鲁肽注射液上市申请","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00460":1},"content_text":"SIHUAN PHARM (00460) announced that the marketing application for semaglutide injection developed by its non-wholly owned subsidiary Huisheng Biopharmaceutical Co., Ltd. has been accepted by the National Medical Products Administration (NMPA) for improving blood glucose control in adults with Type 2 diabetes. Additionally, the weight loss indication for semaglutide injection has completed Phase III clinical enrollment and is currently in the follow-up stage.\nAccording to reports, semaglutide injection is a once-weekly long-acting GLP-1 receptor agonist (GLP-1RA) that activates GLP-1 receptors to enhance insulin secretion in a glucose-dependent manner, suppress glucagon secretion, and delay gastric emptying, thereby achieving blood glucose reduction effects. Meanwhile, semaglutide can reduce appetite and food intake, helping patients decrease caloric consumption and achieve weight reduction.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}